定义前列腺癌病灶大小与局灶治疗边界:病灶内异质性是否影响多参数MRI表现?
该研究评估病灶内异质性对多参数MRI(mpMRI)判断前列腺癌范围和局灶治疗(FT)边界的影响。纳入70例因器官局限前列腺癌行根治性前列腺切除术的男性,全标本切片分别标记低级别(Gleason 3)和高级别(Gleason 4-5)成分。结果显示mpMRI对肿瘤大小的估计及FT边界受肿瘤大小和病灶内分级异质性影响。
要点
- 高级别成分占比≥50%的肿瘤,病理与MRI大小相关性优于<50%者。
- mpMRI对较大肿瘤(>12 mm)和含高级别成分者更容易低估大小。
- 直径≤12 mm肿瘤,5 mm和6 mm边界分别达98.6%和100%完全消融。
核心结论
- mpMRI估计前列腺癌大小及据此确定FT治疗边界受肿瘤大小和病灶内分级异质性影响。
研究设计与样本
- 回顾性分析70例因器官局限前列腺癌行初次根治性前列腺切除术的男性,共122个MRI检出病灶。
- 全标本切片分别标记低级别(Gleason 3)和高级别(Gleason 4-5)成分,校正标本收缩后与mpMRI匹配。
主要发现
- 病理与MRI尺寸总体相关性r=0.79(P<0.001)。
- 高级别癌占比≥50%的肿瘤尺寸相关性优于<50%者(r=0.84 vs r=0.63;P=0.007)。
- mpMRI低估尺寸在>12 mm肿瘤中占51%,≤12 mm中占26%;含高级别癌者占44%,仅低级别者占20%。
关键数值与推荐
- 标本平均线性收缩为8.4%。
- 尺寸差异分析提示FT最佳肿瘤大小为≤12 mm,治疗边界为5-6 mm。
- 直径≤12 mm肿瘤,应用5 mm和6 mm边界分别实现98.6%和100%完全肿瘤消融。
- 所有大小肿瘤应用相同边界可消融>95%的高级别癌成分。
临床怎么用
- FT术前规划应结合肿瘤大小和病灶内高级别成分比例,对>12 mm或含高级别癌者考虑更充分边界。
局限性
- 摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the impact of intralesional heterogeneity on the performance of multiparametric magnetic resonance imaging (mpMRI) in determining cancer extent and treatment margins for focal therapy (FT) of prostate cancer. PATIENTS AND METHODS: We identified men who underwent primary radical prostatectomy for organ- confined prostate cancer over a 3-year period. Cancer foci on whole-mount histology were marked out, coding low-grade (LG; Gleason 3) and high-grade (HG; Gleason 4-5) components separately. Measurements of entire tumours were grouped according to intralesional proportion of HG cancer: 0%, <50% and ≥50%; the readings were corrected for specimen shrinkage and correlated with matching lesions on mpMRI. Separate measurements were also taken of HG cancer components only, and correlated against entire lesions on mpMRI. Size discrepancies were used to derive the optimal tumour size and treatment margins for FT. RESULTS: There were 122 MRI-detected cancer lesions in 70 men. The mean linear specimen shrinkage was 8.4%. The overall correlation between histology and MRI dimensions was r = 0.79 (P < 0.001). Size correlation was superior for tumours with high burden (≥50%) compared to low burden (<50%) of HG cancer (r = 0.84 vs r = 0.63; P = 0.007). Size underestimation by mpMRI was more likely for larger tumours (51% for >12 mm vs 26% for ≤12 mm) and those containing HG cancer (44%, vs 20% for LG only). Size discrepancy analysis suggests an optimal tumour size of ≤12 mm and treatment margins of 5-6 mm for FT. For tumours ≤12 mm in diameter, applying 5- and 6-mm treatment margins would achieve 98.6% and 100% complete tumour ablation, respectively. For tumours of all sizes, using the same margins would ablate >95% of the HG cancer components. CONCLUSIONS: Multiparametric MRI performance in estimating prostate cancer size, and consequently the treatment margin for FT, is impacted by tumour size and the intralesional heterogeneity of cancer grades.
引用
- Aslim EJ, Law YXT, Fook-Chong SMC, et al. Defining prostate cancer size and treatment margin for focal therapy: does intralesional heterogeneity impact the performance of multiparametric MRI? BJU Int. 2021. PMID: 33539650. doi:10.1111/bju.15355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。